GWM Advisors LLC acquired a new stake in Allergan plc (NYSE:AGN) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 2,000 shares of the company’s stock, valued at approximately $341,000.
A number of other institutional investors also recently added to or reduced their stakes in AGN. Cable Hill Partners LLC boosted its position in Allergan by 255.2% in the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after buying an additional 370 shares during the period. Rockefeller Financial Services Inc. boosted its position in Allergan by 283.7% in the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after buying an additional 400 shares during the period. BB&T Investment Services Inc. boosted its position in Allergan by 1,308.2% in the 3rd quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock valued at $139,000 after buying an additional 641 shares during the period. Phocas Financial Corp. purchased a new stake in Allergan in the 2nd quarter valued at about $150,000. Finally, Acropolis Investment Management LLC purchased a new stake in Allergan in the 4th quarter valued at about $153,000. 79.76% of the stock is owned by institutional investors.
Allergan plc (NYSE AGN) opened at $164.04 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.88 and a current ratio of 2.04. The company has a market cap of $54,556.91, a P/E ratio of -12.22, a P/E/G ratio of 1.16 and a beta of 1.19. Allergan plc has a 52 week low of $156.00 and a 52 week high of $256.80.
Allergan (NYSE:AGN) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, topping the consensus estimate of $4.74 by $0.12. The firm had revenue of $4.33 billion during the quarter, compared to analyst estimates of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. Allergan’s revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.90 EPS. analysts forecast that Allergan plc will post 15.57 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.76%. The ex-dividend date of this dividend is Tuesday, February 27th. This is a positive change from Allergan’s previous quarterly dividend of $0.70. Allergan’s payout ratio is -20.86%.
In other news, Director Christopher J. Coughlin acquired 10,000 shares of Allergan stock in a transaction that occurred on Tuesday, December 5th. The stock was purchased at an average price of $163.30 per share, for a total transaction of $1,633,000.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider William Meury sold 11,807 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. In the last quarter, insiders have purchased 17,630 shares of company stock valued at $2,890,057. 0.36% of the stock is currently owned by company insiders.
AGN has been the subject of several research reports. Cantor Fitzgerald set a $191.00 price objective on shares of Allergan and gave the company a “hold” rating in a research report on Tuesday, December 12th. Vetr cut shares of Allergan from a “hold” rating to a “sell” rating and set a $180.97 price objective for the company. in a research report on Monday, January 22nd. Bank of America boosted their price objective on shares of Allergan from $208.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Deutsche Bank reissued a “buy” rating and issued a $215.00 price objective on shares of Allergan in a research report on Tuesday, January 9th. Finally, ValuEngine cut shares of Allergan from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company. Allergan has a consensus rating of “Buy” and an average target price of $227.23.
ILLEGAL ACTIVITY WARNING: “GWM Advisors LLC Takes $341,000 Position in Allergan plc (AGN)” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/02/18/gwm-advisors-llc-takes-341000-position-in-allergan-plc-agn.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.